Olema Pharmaceuticals (OLMA) News Today $3.33 -0.01 (-0.30%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$3.47 +0.14 (+4.20%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2 at 4:30 PM | globenewswire.comHighTower Advisors LLC Takes $510,000 Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)HighTower Advisors LLC bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 87,476 shares of the company's stock, valuedMarch 31 at 3:10 AM | marketbeat.comJPMorgan Chase & Co. Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $28.00JPMorgan Chase & Co. decreased their price objective on Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Friday.March 29, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Price Target Cut to $28.00 by Analysts at JPMorgan Chase & Co.March 29, 2025 | americanbankingnews.comOlema Oncology price target lowered to $28 from $30 at JPMorganMarch 28, 2025 | markets.businessinsider.comPier Capital LLC Invests $1.59 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Pier Capital LLC purchased a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 272,372 shares of the company's stock, valued at approximately $1,588,000. PiMarch 26, 2025 | marketbeat.comOlema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual MeetingMarch 25, 2025 | globenewswire.comFY2025 Earnings Estimate for OLMA Issued By Lifesci CapitalOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Analysts at Lifesci Capital cut their FY2025 EPS estimates for shares of Olema Pharmaceuticals in a research report issued on Wednesday, March 19th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings per sMarch 22, 2025 | marketbeat.comHC Wainwright Issues Optimistic Estimate for OLMA EarningsOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now anticipates that thMarch 22, 2025 | marketbeat.comVictory Capital Management Inc. Sells 758,412 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Victory Capital Management Inc. trimmed its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 89.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 93,100 shares of the company's stock after selling 758,412 shares during the perMarch 22, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for OLMA FY2029 Earnings?Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - HC Wainwright issued their FY2029 EPS estimates for Olema Pharmaceuticals in a report released on Wednesday, March 19th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($2.41) per share for the year. HC WaMarch 21, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Caribou Biosciences (CRBU), Olema Pharmaceuticals (OLMA) and Privia Health Group (PRVA)March 20, 2025 | markets.businessinsider.comOlema Pharmaceuticals (NASDAQ:OLMA) Given "Outperform" Rating at OppenheimerOppenheimer reiterated an "outperform" rating and issued a $25.00 price objective (down previously from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday.March 20, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday.March 20, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Issues Earnings Results, Beats Expectations By $0.12 EPSOlema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.12.March 19, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPSOlema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.12.March 19, 2025 | marketbeat.comOlema Oncology price target lowered to $25 from $30 at OppenheimerMarch 19, 2025 | markets.businessinsider.comOlema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating ResultsMarch 18, 2025 | globenewswire.comOlema Pharmaceuticals (NASDAQ:OLMA) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday.March 6, 2025 | marketbeat.comOlema updated palazestrant combination trial, says OppenheimerMarch 5, 2025 | markets.businessinsider.comOlema Pharmaceuticals (OLMA) Receives a Buy from OppenheimerMarch 5, 2025 | markets.businessinsider.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2025 | globenewswire.comOlema Pharmaceuticals (OLMA) Expected to Announce Earnings on MondayOlema Pharmaceuticals (NASDAQ:OLMA) will be releasing earnings before the market opens on Monday, March 10, Financial Modeling Prep reports.March 3, 2025 | marketbeat.comOlema Oncology to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 20, 2025 | markets.businessinsider.comOlema Oncology appoints Shawnte Mitchell as Chief Legal OfficerFebruary 18, 2025 | markets.businessinsider.comOlema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate SecretaryFebruary 18, 2025 | markets.businessinsider.comOlema Oncology Appoints Shawnte M. Mitchell, J.D.February 18, 2025 | globenewswire.comOlema Pharmaceuticals: Interesting But Undifferentiated DataFebruary 17, 2025 | seekingalpha.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest UpdateOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 8,410,000 shares, a decline of 22.6% from the January 15th total of 10,870,000 shares. Based on an average trading volume of 1,070,000 shares, the days-to-cover ratio is presently 7.9 days.February 15, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Trading Down 5.4% - Time to Sell?Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 5.4% - Should You Sell?February 13, 2025 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 4, 2025 | globenewswire.comOlema Oncology to Participate in Upcoming Investor ConferencesFebruary 3, 2025 | globenewswire.comJPMorgan Chase & Co. Buys 157,171 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)JPMorgan Chase & Co. lifted its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 658.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 181,032 shares of the company's stock after acquiring an additional 157,171 shares during the pJanuary 22, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Acquires 94,651 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 80.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 212,246 shares of theJanuary 19, 2025 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of "Buy" from AnalystsOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) has been given a consensus recommendation of "Buy" by the six ratings firms that are currently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month pricJanuary 16, 2025 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Bain Capital Life Sciences Inv Buys 300,000 SharesJanuary 14, 2025 | insidertrades.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Acquires $1,728,000.00 in StockOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of Olema Pharmaceuticals stock in a transaction on Wednesday, January 8th. The stock was purchased at an average price of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the acquisition, the insider now directly owns 7,800,000 shares of the company's stock, valued at $44,928,000. This represents a 4.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.January 13, 2025 | marketbeat.comOlema Oncology files $200M mixed securities shelfJanuary 7, 2025 | markets.businessinsider.comOlema Oncology files to sell 27.53M shares of common stock for holdersJanuary 3, 2025 | markets.businessinsider.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | globenewswire.comOlema Oncology to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | globenewswire.comGeode Capital Management LLC Decreases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Geode Capital Management LLC lessened its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 11.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 934,929 shares of the company's stock aJanuary 1, 2025 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of "Buy" by BrokeragesShares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have been given an average recommendation of "Buy" by the six research firms that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month tarDecember 22, 2024 | marketbeat.comG. Walmsley Graham Sells 700,761 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) StockDecember 18, 2024 | insidertrades.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $4,730,136.75 in StockOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director G. Walmsley Graham sold 700,761 shares of the company's stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $6.75, for a total value of $4,730,136.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.December 17, 2024 | marketbeat.comWellington Management Group LLP Buys 97,428 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Wellington Management Group LLP grew its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 10.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,002,685 shares of the coDecember 15, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 207,565 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Charles Schwab Investment Management Inc. lifted its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 168.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 330,761 shares of the companDecember 15, 2024 | marketbeat.comHC Wainwright Has Strong Forecast for OLMA FY2024 EarningsOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Investment analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for Olema Pharmaceuticals in a report issued on Wednesday, December 11th. HC Wainwright analyst E. Bodnar now anticipates that the company will earnDecember 13, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $77,358.72 in StockDecember 12, 2024 | insidertrades.comTD Cowen Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)December 12, 2024 | markets.businessinsider.com Remove Ads Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address OLMA Media Mentions By Week OLMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OLMA News Sentiment▼0.140.55▲Average Medical News Sentiment OLMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OLMA Articles This Week▼63▲OLMA Articles Average Week Remove Ads Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MLYS News SYRE News ELVN News COLL News NRIX News VIR News PAHC News XERS News OCS News ZYME News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OLMA) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OLMA Stock Free OLMA Stock Alerts